Contact:
4008465777
-
About Us
News & Events
-
03-20
Tonghua Dongbao Doses the First Patient in Phase III Clinical Trials of Insulin Degludec/Liraglutide Injection
Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or "the Company") has completed the Phase I clinical trial in China for Insulin Degludec/Liraglutide Injection following the receipt of a cl...
-
03-03
GLP-1 Global Expansion | Tonghua Dongbao's Liraglutide Injection Undergoes GMP Inspection by the Egyptian Ministry of Health and Population
Recently, the liraglutide injection, developed by Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or "the Company") and its partner, Kexing Biopharm Co., Ltd. ("Kexing Biopharm"), received...
-
02-27
Tonghua Dongbao's THDBH120 Injection Meets Primary Endpoint in Phase Ib Trial for Type 2 Diabetes, Reducing HbA1c by 1.38% in Six Weeks
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), completed a Phase Ib pivotal clinical...
-
02-13
Tonghua Dongbao's Dual GLP-1/GIP Receptor Agonist (THDBH120 Injection) Meets Primary Endpoint in Phase Ib Trial for Weight Loss, Reducing Weight by 9.36% in Six Weeks
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), completed a Phase Ib pivotal clinical...
-
01-22
Tonghua Dongbao Receives Marketing Approval for Etoricoxib Tablets, Advancing Its Entry into the Gout Market
Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") has recently received a Drug Registration Certificate for etoricoxib tablets from the National Medical Products Administra...
-
08-01
Tonghua Dongbao: First Patient Dosed in Phase III Clinical Trial of Semaglutide Injection (THDB0225 Injection)
In May 2024, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter referred to as "Tonghua Dongbao" or "the Company") signed the Commercialization Licensing and Marketing Authorization Holder (MAH) Ag...